U.S. markets closed

Inari Medical, Inc. (NARI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.23-1.39 (-2.33%)
At close: 04:00PM EDT
58.50 +0.27 (+0.46%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close59.62
Bid58.10 x 1000
Ask58.00 x 800
Day's Range55.33 - 61.39
52 Week Range50.50 - 100.00
Avg. Volume827,706
Market Cap3.093B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.01
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
0% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NARI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inari Medical, Inc.
    NARI: Raising target price to $65.00INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Inari Medical Announces Launch of 2021 Ethos and Sustainability Report

    IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the publication of its first ever “Ethos and Sustainability Report.” The report highlights Inari’s commitment to its ethos, and as part of that to environmental, social and governance (ESG) leadership. The report can be found on Inari’s website here. “I am proud to is

  • Zacks

    Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

    Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

  • Benzinga

    Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

    View more earnings on NARISee more from BenzingaQuidel Clocks More Than Three-Fold Jump In COVID-19 ProductsPacific Biosciences Clocks 14% Jump In Q1 RevenuesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga does not provide investment advice. All rights reserved.